Parkinson's drug discontinuation study: safety first

NCT ID NCT07214285

Completed Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows one Parkinson's patient who has been receiving A-dopamine directly into the brain via a pump for years. The goal is to monitor safety during long-term use and manage a gradual, individualized dose reduction until the treatment stops, switching to an alternative like Scyova. It aims to prevent complications from abrupt discontinuation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A-dopamine (anaerobic dopamine) delivered via intracerebral pump
What this could lead to: If successful, this study could show that gradual dose reduction and switching to alternative treatments like Scyova is safe for Parkinson's patients.
What could go wrong: This is a very small follow-up study (only 1 participant) focused on safety, not effectiveness. The treatment is being discontinued, so it won't provide new evidence on long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

UHLillle

Lille, Haut de France, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.